8.98

1.32% -0.12

After Hours: 9.10 0.12 +1.34%

Delcath Systems Inc (DCTH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Delcath Systems Inc stock is traded at $8.98, with a volume of 306.28K. It is down -1.32% in the last 24 hours and down -9.75% over the past month. Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Previous Close:

$9.10

Open:

$9.01

24h Volume:

306.28K

Relative Volume:

0.65

Market Cap:

$312.02M

Revenue:

$85.23M

Net Income/Loss:

$2.70M

P/E Ratio:

142.99

EPS:

0.0628

Net Cash Flow:

$20.97M

1W Performance:

-7.80%

1M Performance:

-9.75%

6M Performance:

-18.59%

1Y Performance:

-35.67%

1-Day Range:

$8.91

$9.06

1-Week Range:

$8.90

$9.72

52-Week Range:

$8.12

$18.23

Delcath Systems Inc Stock (DCTH) Company Profile

Name

Delcath Systems Inc

Sector

Healthcare (1113)

Industry

Medical Devices (144)

Phone

(518) 743-8892

Address

566 QUEENSBURY AVENUE, QUEENSBURY, NY

Employee

156

Twitter

@delcathsystems

Next Earnings Date

2024-11-08

Latest SEC Filings

DCTH's Discussions on Twitter

Compare DCTH vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DCTH Delcath Systems Inc	8.98	316.19M	85.23M	2.70M	20.97M	0.0628
ABT Abbott Laboratories	104.06	182.20B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	328.51	127.28B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	86.58	111.92B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	68.15	103.35B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	81.69	47.64B	6.07B	1.06B	1.34B	1.8063

Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-28-24	Initiated	Craig Hallum	Buy
May-14-24	Initiated	Stephens	Overweight
Jul-26-22	Resumed	Canaccord Genuity	Buy
Dec-10-21	Initiated	H.C. Wainwright	Buy
Mar-09-21	Initiated	Canaccord Genuity	Buy
Jan-05-21	Initiated	BTIG Research	Buy
Jun-01-20	Initiated	Laidlaw	Buy

View All

Delcath Systems Inc Stock (DCTH) Latest News

Mar 23, 2026

Form 13G DELCATH SYSTEMS For: 20 March By Investing.com - Investing.com Australia

Mar 20, 2026

Mar 19, 2026

Risk Recap: Can CMCT reach all time highs this yearEarnings Trend Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn

Mar 19, 2026

Mar 18, 2026

Daniel Kaufman reports 5.08% stake in Delcath Systems (DCTH) - Stock Titan

Mar 18, 2026

Mar 16, 2026

Divisadero Street Capital Management LP Invests $5.12 Million in Delcath Systems, Inc. $DCTH - MarketBeat

Mar 16, 2026

Mar 13, 2026

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 from Inve - Yahoo

Mar 13, 2026

Mar 12, 2026

The Technical Signals Behind (DCTH) That Institutions Follow - Stock Traders Daily

Mar 12, 2026

Mar 11, 2026

Delcath Systems Charts Profitable Path Amid Heavy Investment - The Globe and Mail

Mar 11, 2026

Delcath Systems Q3 2025 Earnings Preview - MSN

Mar 11, 2026

Mar 10, 2026

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail

Mar 10, 2026

Mar 09, 2026